Recognizing the significant influence of non-tumor cells in the TME on CDK4/6i response [56], we examined the composition and transcriptomic profiles in HR+/HER2- BC metastases before and after CDK4/6i treatment. The gene discussed is CDK4; the disease is neoplasm.